OPKO Health’s ModeX Therapeutics Will Present Data Demonstrating In Vivo CAR-T Cell Generation and Deep B-Cell Depletion in Preclinical Studies

Multispecific antibody conjugated LNP/mRNA platform enables in vivo T-cell engineering and systemic B-cell depletion in animal models Data will ...
Yahoo Finance

OPKO Health’s ModeX Therapeutics Announces Epstein-Barr Virus Vaccine Candidate Enters Phase I Clinical Study in Collaboration with Merck

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
FierceBiotech

Regeneron pledges more than $1B biobucks for ModeX multispecific antibodies

Regeneron is buying in to Modex Therapeutics’ next-generation antibody platform with a $7 million upfront payment and a total potential deal value exceeding $1 billion. The New York-based biopharma ...
FierceBiotech

ModeX nets up to $168M in BARDA bucks to develop therapies for viral infections

The big-time BARDA contracts keep rolling in, this time for infectious disease biotech and Merck partner ModeX Therapeutics. The company has hauled in a $168 million contract from the Biomedical ...
Seeking Alpha

ModeX Therapeutics Secures $35 Million BARDA Supplement to Develop COVID Multispecific Antibodies and $16 Million to Initiate Influenza Program

Brings total awards from BARDA to $110 million for development of broad SARS-CoV-2 and Influenza multispecifics, with potential funding of up to $205 million if all options are executed Development ...
Nasdaq

ModeX Therapeutics Establishes Scientific Advisory Board to Enhance Development of Multispecific Antibodies for Complex Diseases

ModeX Therapeutics Inc., an OPKO Health company, announced the formation of a Scientific Advisory Board to support the development of its immunology and oncology pipeline, which includes ...
Nasdaq

ModeX Therapeutics Secures BARDA Contract to Develop Novel Multispecific Antibodies Against Viral Infectious Disease Threats

NATICK, Mass., Sept. 28, 2023 (GLOBE NEWSWIRE) -- ModeX Therapeutics Inc., an OPKO Health, Inc. company (NASDAQ: OPK), has been awarded a contract from the Biomedical Advanced Research and Development ...